Stryker Corporation

New York Stock Exchange
Back to all articles
Slightly Bullish +15

AIA Group Ltd Sells 1,624 Shares of Stryker Corporation $SYK

📉 AIA Group Ltd sold 1,624 shares of Stryker in Q1, reducing its stake by 8.4% to a remaining value of $5.829 million.

🆕 Multiple hedge funds including Sankala Group LLC and DJE Kapital AG established new positions in SYK valued between $26,000 and $28,000.

📊 Institutional investors own 77.09% of Stryker Corporation's outstanding shares.

📉 Wells Fargo cut its price target to $418.00 while maintaining an 'overweight' rating on the stock.

🎯 BMO Capital Markets initiated coverage with an 'outperform' rating and a $369.00 price target.

💰 The consensus analyst price target for SYK is $392.52 with an average rating of 'Moderate Buy'.

📉 Stryker reported Q1 EPS of $2.60, missing the consensus estimate of $2.98 by $0.38.

💵 Revenue for the quarter was $6.02 billion, representing a 2.6% increase compared to the prior year.

📉 The stock missed revenue expectations of $6.34 billion during the first quarter.

📈 Stryker set full-year 2026 EPS guidance between $14.90 and $15.10.

💸 Corporate insiders sold approximately 323,264 shares valued at over $100 million in the last three months.

📉 VP Robert S. Fletcher sold 4,544 shares for $1.39 million under a pre-arranged trading plan.

💰 The company declared a quarterly dividend of $0.88 per share with an ex-dividend date of June 30th.

📉 VP M Kathryn Fink sold 5,220 shares for $1.48 million in early May.

📊 Stryker trades at a P/E ratio of 37.01 with a market capitalization of $122.59 billion.

📉 The stock price is currently below its 200-day moving average of $336.71.

🏥 Stryker operates in orthopedics, surgical equipment, neurotechnology, and patient-handling equipment sectors.

📈 The company maintains a quick ratio of 1.25 and a current ratio of 2.11.

📉 Net margin for the quarter was 13.20% with a return on equity of 23.42%.

📅 Analysts anticipate Stryker will post $14.99 EPS for the current fiscal year.

Bullish Signals
  • Multiple institutional investors including Sankala Group LLC, Godfrey Financial Associates Inc., and DJE Kapital AG established new positions in Stryker during Q3 or Q4.
  • BMO Capital Markets initiated coverage with an 'outperform' rating and a $369.00 price target.
  • Stryker reported a 2.6% year-over-year revenue increase to $6.02 billion despite missing consensus estimates.
  • The company maintains a strong balance sheet with a quick ratio of 1.25, current ratio of 2.11, and debt-to-equity ratio of 0.62.
  • Stryker has set full-year 2026 EPS guidance between $14.90 and $15.10, with analysts expecting $14.99.
  • The company declared a quarterly dividend of $0.88 per share representing an annualized yield of 1.1%.
Risk Factors
  • Stryker reported Q1 EPS of $2.60, missing the consensus estimate of $2.98 by $0.38.
  • Revenue for the quarter was $6.02 billion, falling short of the $6.34 billion consensus forecast.
  • Corporate insiders sold approximately 323,264 shares valued at over $100 million in the last three months.
  • Vice Presidents Robert S. Fletcher and M Kathryn Fink reduced their personal holdings by over 28% each in May transactions.
  • The stock price is currently trading below its 200-day moving average of $336.71.
  • Wells Fargo & Company lowered its price objective from $456.00 to $418.00.
Full Analysis
AIA Group Ltd reduced its stake in Stryker Corporation (NYSE:SYK) by 8.4% in the first quarter, selling 1,624 shares to hold a remaining position of 17,738 shares valued at $5.829 million. While AIA decreased its holdings, several other institutional investors including Sankala Group LLC, Godfrey Financial Associates Inc., and DJE Kapital AG established new positions in the medical technology company during the third or fourth quarter, with individual stakes ranging from approximately $26,000 to $28,000. Institutional ownership of SYK remains high at 77.09%. Analyst sentiment for Stryker is mixed but generally positive, with a consensus target price of $392.52 and an average rating of 'Moderate Buy' based on data from MarketBeat.com. Wells Fargo & Company lowered its price objective to $418.00 while maintaining an 'overweight' rating, whereas BMO Capital Markets initiated coverage with an 'outperform' rating and a $369.00 target. The stock currently trades around $319.78, trading below its 200-day moving average of $336.71 but above its 50-day moving average of $312.69. Financially, Stryker reported Q1 earnings of $2.60 EPS, missing the consensus estimate of $2.98 by $0.38, with revenue of $6.02 billion falling short of the $6.34 billion forecast. Despite the miss, the company posted a 2.6% year-over-year revenue increase and maintains strong balance sheet metrics including a P/E ratio of 37.01 and a debt-to-equity ratio of 0.62. The company has set full-year 2026 EPS guidance between $14.90 and $15.10, with analysts expecting $14.99. Corporate insiders have been active sellers recently, with Vice Presidents Robert S. Fletcher and M Kathryn Fink reducing their personal holdings by over 28% each in May transactions totaling nearly $2.9 million combined. In total, corporate insiders sold approximately 323,264 shares valued at over $100 million in the last three months. The company also declared a quarterly dividend of $0.88 per share payable on July 31st to shareholders of record on June 30th, representing an annualized yield of 1.1%.